Product
Rapamycin
Aliases
Rapacan, Rapamune, Raparen, Rapasim (3 other aliases)
4 clinical trials
1 drug
6 indications
Indication
AgingIndication
Mild Cognitive ImpairmentIndication
Alzheimer's diseaseIndication
Chronic Fatigue SyndromeIndication
EpigeneticsIndication
Inflammatory MediatorsDrug
rapamycinClinical trial
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL): A Prospective, Double-Blind, Placebo-Controlled Trial for Rapamycin in Healthy Individuals Assessing Safety and Efficacy in Reducing Aging EffectsStatus: Completed, Estimated PCD: 2023-12-30
Clinical trial
Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH)Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Rapamycin in Myalgic Encephalomyelitis/Chronic Fatigue SyndromeStatus: , Estimated PCD: 2025-12-11
Clinical trial
An Innovative Proof-of-concept Approach to Identify Age-modulating Drugs Capable of Reversing Inflammation and Re-setting the Epigenetic Clock (Topical-RAPA)Status: Completed, Estimated PCD: 2022-04-15